Curacle Co., Ltd. (365270)

Overview

Curacle Co., Ltd. is a bio-venture company deeply engrossed in the innovative pursuit of developing pharmaceutical solutions for diseases predominantly triggered by the aging process and vascular damages. Since its inception in 2016, the enterprise has established its foundational base in Seoul, South Korea, specializing in addressing a spectrum of health concerns including age-related vascular diseases, challenging metabolic conditions, and cancer through both targeting mechanisms and immunotherapy approaches.

Products and Services

CU06: This product is a multifaceted therapeutic candidate aimed at addressing a range of medical conditions such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke, as well as being potentially used concomitantly with immunotherapy. It also shows promise in treating inflammatory bowel disease and hereditary angioedema. The diverse applicability of CU06 underscores its potential in altering the treatment landscape of various conditions linked with vascular damage and inflammation.

CU03: Currently in Phase 2a clinical trial, CU03 is being developed as a treatment option for age-related macular degeneration, a leading cause of vision loss. This product's advancement to later stages of clinical trials showcases Curacle’s dedication towards combating degenerative eye diseases associated with aging, highlighting its potential impact on improving patients' quality of life.

CU01: This medicine, specializing in the treatment of diabetic nephropathy, has successfully completed its Phase 2a clinical trial. Diabetic nephropathy, a serious complication of diabetes resulting in chronic kidney disease, represents a significant unmet medical need, and CU01’s development reflects Curacle’s commitment to addressing such critical health issues through innovative research and development.

CU02: Targeted for the treatment of nonalcoholic steatohepatitis (NASH), CU02 lies within Curacle’s back-up pipeline. NASH, a more severe form of nonalcoholic fatty liver disease, is a growing health concern globally, and CU02's development indicates Curacle's proactive approach in offering potential therapeutic solutions for metabolic diseases.

CU04: Designed as a c-Myc inhibitor, CU04 is part of the company's arsenal against cancer. By targeting the c-Myc oncogene, known for promoting cancer cell proliferation, CU04 embodies Curacle’s strategic focus on halting cancer progression through molecular targeting, offering hope for new cancer therapies.

CU05: Another innovative anti-cancer product, CU05, functions as an Amigo2-PDK1 inhibitor. This approach illustrates Curacle’s commitment to diversifying its cancer treatment modalities, focusing on disrupting cancer cell survival pathways, thereby broadening the therapeutic options for cancer patients.